Conversion of initially unresectable hepatocellular carcinoma (HCC) with triple-combination therapy (lenvatinib, anti-PD-1 antibodies, and transarterial therapy): A retrospective analysis

被引：11
|
作者：
Song, Tianqiang
Lang, Mengran
Lu, Wei
Zhang, Ti
Li, Huikai
Wu, Qiang
Cui, Yunlong
Zhang, Wei
Li, Qiang
Zang, Fenglin
Xing, Wenge
Ren, Shaohua
Gan, Leijuan
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Liver Canc Ctr, Tianjin, Peoples R China
[2] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Canc Inst & Hosp, Intervent Therapy Dept, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
413
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinoma
    Wen, Yaohong
    Fu, Shunjun
    He, Guolin
    Cai, Lei
    Liu, Yahong
    Li, Xinmin
    Xu, Yuyan
    Wang, Chunming
    Zhong, Kaihang
    Zhang, Cheng
    Xie, Qingyu
    Pan, Mingxin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
    Yi, Yong
    Sun, Bao-Ye
    Weng, Jia-Lei
    Zhou, Cheng
    Zhou, Chen-Hao
    Cai, Ming-Hao
    Zhang, Jing-Yun
    Gao, Hong
    Sun, Jian
    Zhou, Jian
    Fan, Jia
    Ren, Ning
    Qiu, Shuang-Jian
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ge, Ning-Ling
    Chen, Yi
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
    Gan, Leijuan
    Lang, Mengran
    Tian, Xindi
    Ren, Shaohua
    Li, Guangtao
    Liu, Yayue
    Han, Ruyu
    Zhu, Kangwei
    Li, Huikai
    Wu, Qiang
    Cui, Yunlong
    Zhang, Wei
    Fang, Feng
    Li, Qiang
    Song, Tianqiang
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 673 - 686
  • [5] Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
    Wu, Shao-Jie
    Ruan, Dan-Dan
    Wu, Qiu-Yan
    Tang, Yi
    Zhang, Jian-Hui
    Cai, Sen-Lin
    Zhou, Yan-Feng
    Luo, Jie-Wei
    Fang, Zhu -Ting
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 807 - 820
  • [6] Early tumor marker decrease to predict the efficacy of combination therapy with lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC).
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ge, Ning-Ling
    Zhu, Jin-Jin
    Xu, Bin
    Chen, Yi
    Li, Mei-Ling
    Zhou, Jian
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [7] Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study
    Zhang, Jinliang
    Zhang, Xihao
    Mu, Han
    Yu, Ge
    Xing, Wenge
    Wang, Lu
    Zhang, Ti
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Comparison of anti-PD-L1 with anti-PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.
    Li, Shaohua
    Mei, Jie
    Wang, Qiaoxuan
    Zhao, Rongce
    Lu, Lianghe
    Deng, Min
    Lin, Wenping
    Guan, Renguo
    Wen, Yuhua
    Zheng, Lie
    Wei, Wei
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 509 - 509
  • [9] Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma
    Yu, Bingran
    Zhang, Ning
    Feng, Yun
    Zhang, Yongfa
    Zhang, Ti
    Wang, Lu
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1709 - 1721
  • [10] Efficacy and safety of donafenib combined with anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma (HCC): A retrospective real-world study.
    Liu, Sulai
    Zhou, Shuyi
    Song, Yinghui
    Liu, Jianming
    Guo, Chao
    Yang, Pingzhou
    Li, Ou
    Yi, Weimin
    Peng, Chuang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345